Polzin A, Stroman J, Schaap R, Baird R, Sturdevant D, Gurumoorthy A
Hosp Pract (1995). 2025; 53(1):2455930.
PMID: 39825620
PMC: 11885032.
DOI: 10.1080/21548331.2025.2455930.
Rodrigues A, Goncalves L, Gregorio T, Baldaia C, Santo G, Gouveia J
J Clin Med. 2024; 13(22).
PMID: 39597986
PMC: 11595216.
DOI: 10.3390/jcm13226842.
Hays W, Billups K, Nicholson J, Bailey A, Gregory H, Weeda E
J Thromb Thrombolysis. 2024; 58(2):276-283.
PMID: 39467897
PMC: 11885330.
DOI: 10.1007/s11239-024-03052-4.
Leblanc K, Edwards S, Dranitsaris G, Leong D, Carrier M, Malone S
Cancers (Basel). 2024; 16(19).
PMID: 39409956
PMC: 11475820.
DOI: 10.3390/cancers16193336.
Sarhan K, Mohamed R, Elmahdi R, Mohsen Y, Elsayed A, Zayed D
Neurocrit Care. 2024; .
PMID: 39379749
DOI: 10.1007/s12028-024-02130-y.
Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding.
Muir I, Herzog E, Brechmann M, Ghobrial O, Rezvani Sharif A, Hoffman M
PLoS One. 2024; 19(9):e0310883.
PMID: 39331637
PMC: 11432878.
DOI: 10.1371/journal.pone.0310883.
Long-Term Safety of a Four-Factor Prothrombin Complex Concentrate (Kcentra®/Beriplex® P/N): An Updated Pharmacovigilance Review.
Milling T, Voronov A, Schmidt D, Lindhoff-Last E
Thromb Haemost. 2024; 125(1):46-57.
PMID: 39074810
PMC: 11698618.
DOI: 10.1055/s-0044-1788305.
Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors.
Fera T, Burnett A, Grandoni J, Moore M, Nussbaum B, Pollack Jr C
J Pharm Pract. 2024; 38(1):7-12.
PMID: 39030931
PMC: 11639411.
DOI: 10.1177/08971900241263164.
Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine).
Bekka E, Liakoni E
Br J Clin Pharmacol. 2024; 91(3):604-614.
PMID: 38926082
PMC: 11862798.
DOI: 10.1111/bcp.16142.
Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
Pathan S
Hosp Pharm. 2024; 59(4):394-406.
PMID: 38919755
PMC: 11195834.
DOI: 10.1177/00185787241229192.
Andexanet Alfa versus Four-Factor Prothrombin Complex Concentrate for the Reversal of Factor Xa (FXa) Inhibitor-Associated Intracranial Hemorrhage: A Systematic Review of Retrospective Studies.
Ferreira L, Oldemburg R, Leitao Filho J, Cerveira R, Vasconcelos V, da Costa G
J Clin Med. 2024; 13(11).
PMID: 38892788
PMC: 11173120.
DOI: 10.3390/jcm13113077.
A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding.
Desvages M, Borgel D, Adam F, Tu G, Jaouen S, Reperant C
Res Pract Thromb Haemost. 2024; 8(4):102426.
PMID: 38882463
PMC: 11179090.
DOI: 10.1016/j.rpth.2024.102426.
Evaluation and treatment of gastrointestinal bleeding in patients taking anticoagulants presenting to the emergency department.
Singer A, Abraham N, Ganti L, Peacock W, Dark J, Ishaq H
Int J Emerg Med. 2024; 17(1):70.
PMID: 38822267
PMC: 11141076.
DOI: 10.1186/s12245-024-00649-7.
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors.
Goldin M, Smith K, Koulas I, Leung T, Ravi M, Parhar S
TH Open. 2024; 8(2):e209-e215.
PMID: 38741610
PMC: 11090682.
DOI: 10.1055/a-2306-0804.
Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey.
Fasanya C, Arrillaga A, Caronia C, Rothburd L, Japhe T, Hahn Y
Clin Appl Thromb Hemost. 2024; 30:10760296241238013.
PMID: 38494906
PMC: 10946067.
DOI: 10.1177/10760296241238013.
Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study.
Yu J, Li P, Chen D, Huang W, See L
Sci Rep. 2024; 14(1):4771.
PMID: 38413742
PMC: 10899247.
DOI: 10.1038/s41598-024-55500-z.
Definition of factor Xa inhibitor-related, life-threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel.
Fermann G, Cash B, Coelho-Prabhu N, Maegele M, Bingisser R, Sehgal V
J Am Coll Emerg Physicians Open. 2023; 4(5):e13043.
PMID: 37794950
PMC: 10545659.
DOI: 10.1002/emp2.13043.
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Dobesh P, Fermann G, Christoph M, Koch B, Lesen E, Chen H
Res Pract Thromb Haemost. 2023; 7(6):102192.
PMID: 37753225
PMC: 10518480.
DOI: 10.1016/j.rpth.2023.102192.
Prothrombin Complex Concentrate Utilization in Children's Hospitals.
Lutmer J, Mpody C, Sribnick E, Karube T, Tobias J
J Pediatr Intensive Care. 2023; 12(3):219-227.
PMID: 37565019
PMC: 10411157.
DOI: 10.1055/s-0041-1731686.
Propensity matched analysis examining the effect of passive reversal of direct oral anticoagulants on blood loss and the need for transfusions among traumatic geriatric hip fractures.
Meinig R, Jarvis S, Salottolo K, Nwafo N, McNair P, Harrison P
Eur J Med Res. 2023; 28(1):241.
PMID: 37475008
PMC: 10360353.
DOI: 10.1186/s40001-023-01053-2.